No profile data available.
Adaptive Biotechnologies Corporation (ADPT) is a healthcare company in the DNA testing equipment industry, based in Seattle, United States, with about 624 full-time employees.
It reported revenue of $276.98 million for fiscal year 2025, up 54.8% from fiscal year 2024, and net income of -$59.50 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $71.55 million, up 21.5% from a year before. Its largest business segment, Minimal Residual Disease, brought in 77% of segment revenue in fiscal year 2025. Its market capitalization was $4.23 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Adaptive Biotechnologies reported $276.98 million in revenue for fiscal year 2025, up 54.8% from $178.96 million in fiscal year 2024. In Q2 2026 revenue was $71.55 million.
Minimal Residual Disease, with $212.33 million or 77% of segment revenue in fiscal year 2025. Next: Immune Medicine (23%).
$4.23 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include Qiagen N.v. (QGEN), Caris Life Sciences, Inc. (CAI), Grail, Inc. (GRAL), Veracyte, Inc. (VCYT).